Yahoo

Structure’s obesity pill prompts 16.3% weight loss in Phase II

Add Yahoo as a preferred source to see more of our stories on Google. Analysts note that this Phase II readout keeps aleniglipron in line to challenge other oral GLP-1RAs on the market if it were to ...
Business Insider

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...
IEEE

Full Torque-Speed Range Minimum Loss (FT-SRML) Fault Tolerant Control of Dual Three-phase PMSMs Under Open-phase Fault

Abstract: When dual three-phase PMSM (DT-PMSM) operates under open-phase fault, the harmonics in the post-fault currents could substantially degrade system efficiency, maximum torque range and maximum ...
Tennessean

Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...
FierceBiotech

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...
Morningstar

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' ...
Seeking Alpha

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
MarketWatch

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

The MarketWatch News Department was not involved in the creation of this content. -- VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher ...
Nasdaq

Pfizer's Monthly Injectable GLP-1 Delivers Strong, Sustained Weight Loss In Phase 2b Study

(RTTNews) - Pfizer Inc. (PFE) on Tuesday announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its ultra-long-acting, injectable GLP-1 receptor ...
Business Wire

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight ...
Reuters

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

Roche obesity drug shows 22.5% weight loss in Phase-II trial Roche focuses on catching Lilly in $150 billion obesity market Investors lukewarm on CT-388 results in crowded market The company said on ...
Nasdaq

Genentech's CT388 Demonstrates Significant 22.5% Weight Loss In Phase 2 Study

(RTTNews) - Genentech, a biotechnology firm and member of the Roche Group (RHHBY,ROG.SW), announced positive topline results from its Phase 2 clinical trial of CT-388 in obesity. CT-388 is an ...